盤龍藥業(002864.SZ)擬回購2000萬元-4000萬元的股份回購價不超39元/股
格隆匯8月19日丨盤龍藥業(002864.SZ)公佈,公司擬使用自有資金以集中競價交易方式回購公司股份,用於實施員工持股計劃或股權激勵。回購股份的資金總額不低於人民幣2000萬元(含),不超過人民幣4000萬元(含),回購股份價格不超過人民幣39元/股(含39元/股)。回購期限為自公司董事會審議通過之日起12個月內。公司擬通過集中競價交易方式以自有資金回購部分社會公眾股份,用於員工持股計劃或股權激勵。
按照此次回購資金總額上限人民幣4000萬元,以回購價格上限39元/股進行測算,預計回購股份數量約為約102.56萬股,約佔目前總股本的1.18%;按照此次回購資金總額下限人民幣2000萬元,以回購價格上限39元/股進行測算,預計回購股份數量約為約51.28萬股,約佔目前總股本的0.59%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.